Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 16, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 176,754 Ordinary Shares on December 16, 2013.
- Price Range: Highest price paid was 1,583.50 pence; lowest price paid was 1,570.00 pence.
- Treasury Holdings (Settled): 516,339,909 shares (9.61% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,433,663 shares (10.66% of total voting rights).
- Shares in Issue: 4,855,543,899 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 176,754 shares. Consequently, the percentage of total voting rights held in Treasury increased to 10.66% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Points
- Verify the total number of shares in issue (4,855,543,899) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.66% including unsettled shares).
- Note that the repurchased shares are intended to be held in Treasury.